Latest News and Press Releases
Want to stay updated on the latest news?
-
ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions
-
Dépôt auprès de la FDA d’une demande de classification du dispositif ARC-EX® System basée sur les risques (demande « De Novo ») Levée de fonds de 20 millions d’euros Annonce des résultats...
-
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
-
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
-
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
-
ONWARD Medical has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System.
-
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
-
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....
-
NE PAS DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE LA DISTRIBUTION OU LA DIFFUSION SERAIT...
-
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL....